Key Takeaways:
- Radisens Diagnostics is a game changer in the healthcare industry, taking diagnostic testing to the point of care.
- They have developed a portable diagnostic platform that performs routine chronic and acute tests, aiming to close the gap between diagnostics and therapies.
- Focusing on chronic and acute conditions, they offer a comprehensive test menu that is not offered by other devices in the market.
- Their vision is to help drive cost savings in healthcare and improve performance based incentives required by insurers.
With a surge in chronic diseases such as diabetes, heart disease, hypertension, and kidney disease, diagnosis and monitoring at the point of care is a growing need. This is where Radisens Diagnostics, a startup based in Cork, Ireland, comes in. The company has developed portable medical diagnostic platforms and consumables capable of testing blood at the point of care, thereby bridging the gap between diagnostics and therapies.
The value of Point-of-Care Testing (PoCT) is well recognised, especially in the US, as it leads to improved patient outcomes and healthcare cost savings. However, current tests usually measure individual analytes with various instruments that are poorly connected with patient health records, leading to dissatisfaction and inefficiencies. Radisens Diagnostics is aiming to alleviate this situation.
What sets Radisens Diagnostics apart is its visionary approach towards integrating immunochemistry, clinical chemistry, and haematology assays onto multiplexed test panels. The comprehensive test menu covers chronic and acute diseases. Currently, no other device in the market caters to this demand. By utilising just a drop of blood, Radisens’ disruptive platform can provide instant results.
Another differential is their focus on panels for cell counting, cardiac targets, and oncology. With the initial chronic disease panels covering diabetes, heart disease, hypertension and chronic kidney disease, they are contributing largely to the broader healthcare sector by mapping the complete chronic and acute disease pathways.
Looking at the future, there is no doubt that Radisens Diagnostics plays a pivotal role in disrupting the healthcare and patient care industry. The company is looking forward to placing diagnostic devices into every physician’s office and acute hospital setting, to serve chronic and acute conditions. This could realise significant cost savings and enable performance-based incentives as required by insurers.
Keen to learn more? You can visit their website here or join their conversation on Twitter and LinkedIn. Let’s gear up to witness the revolution in point-of-care diagnostic testing that Radisens Diagnostics is set to bring in the healthcare industry.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
